medigraphic.com
Organo Oficial de la Sociedad Mexicana de Urología

2024, Number 3

<< Back Next >>

Rev Mex Urol 2024; 84 (3)

Treatment of non-metastatic castration-resistant prostate cancer: A systematic review and network meta-analysis

Iregui Parra JD, García-Perdomo HA

Language: English
References: 16
Page: 1-14
PDF size: 319.5 Kb.


ABSTRACT

Background: Patients with non-metastatic prostate cancer treated with androgen deprivation therapy develop castration resistance after an average of 19 months. Non-metastatic castration-resistant prostate cancer (M0CRPC) refers to biochemical progression despite medical or surgical castration.
Purpose: To determine the effectiveness of the available interventions for treating non-metastatic castration-resistant prostate cancer (M0CRPC).
Methods: We performed a search strategy in MEDLINE via Ovid, EMBASE, CENTRAL, and LILACS. We included phase II and phase III clinical trials whose primary objective was to evaluate the effectiveness of the intervention in a patient with M0CRPC (primary outcome metastasis-free survival). We excluded studies that included patients with multimodal treatment. We performed the statistical analysis in R and Review Manager 5.3 (RevMan 5.3).
Results: We found a total of 1376 studies. After screening, we selected three studies for qualitative analysis. In the analysis of the three included studies, a total of 4117 patients older than 18 years had non-metastatic castration-resistant prostate cancer. The interventions evaluated were apalutamide, enzalutamide, and darolutamide. All trials demonstrated a significant increase in MFS with the evaluated intervention in patients with nmCRPC. The indirect comparison showed that the three option is better than placebo, but apalutamide and enzalutamide are better than darolutamide.
Conclusion: In non-metastatic patients, CRPC apalutamide and enzalutamide provide a lower risk of metastasis than darolutamide. Also, there were no differences between apalutamide and enzalutamide.


REFERENCES

  1. Iregui Parra, JD: Conceptualization, Methodology,Data curation, Writing - Originaldraft, Review, and editing.

  2. García Perdomo HA: Conceptualization,Methodology, Data curation, Writing - Originaldraft, Proofreading and editing.Conflict of interestNone of the authors have any conflicts of interestor financial ties to disclose.FundingThis research received no specific grant fromany funding agency in the public, commercial,or not-for-profit sectors.References1. Scher HI, Solo K, Valant J, Todd MB, MehraM. Prevalence of Prostate Cancer Clinical Statesand Mortality in the United States: EstimatesUsing a Dynamic Progression Model. PLOSONE. 2015;10(10): e0139440. https://doi.org/10.1371/journal.pone.0139440.2. Chandrasekar T, Yang JC, Gao AC, Evans CP.Mechanisms of resistance in castration-resistantprostate cancer (CRPC). Translational Andrologyand Urology. 2015;4(3): 365–380. https://doi.org/10.3978/j.issn.2223-4683.2015.05.02.

  3. Sharifi N, Dahut WL, Steinberg SM, Figg WD,Tarassoff C, Arlen P, et al. A retrospective studyof the time to clinical endpoints for advancedprostate cancer. BJU international. 2005;96(7):985–989. https://doi.org/10.1111/j.1464-410X.2005.05798.x.

  4. Smith MR, Kabbinavar F, Saad F, HussainA, Gittelman MC, Bilhartz DL, et al. Naturalhistory of rising serum prostate-specific antigenin men with castrate nonmetastatic prostatecancer. Journal of Clinical Oncology: OfficialJournal of the American Society of ClinicalOncology. 2005;23(13): 2918–2925. https://doi.org/10.1200/JCO.2005.01.529.

  5. Scher HI, Morris MJ, Stadler WM, HiganoC, Basch E, Fizazi K, et al. Trial Design andObjectives for Castration-Resistant ProstateCancer: Updated Recommendations Fromthe Prostate Cancer Clinical Trials WorkingGroup 3. Journal of Clinical Oncology: OfficialJournal of the American Society of ClinicalOncology. 2016;34(12): 1402–1418. https://doi.org/10.1200/JCO.2015.64.2702.

  6. Di Nunno V, Mollica V, Santoni M, Gatto L,Schiavina R, Fiorentino M, et al. New HormonalAgents in Patients With NonmetastaticCastration-Resistant Prostate Cancer: Meta-Analysis of Efficacy and Safety Outcomes.Clinical Genitourinary Cancer. 2019;17(5):e871–e877. https://doi.org/10.1016/j.clgc.2019.07.001.

  7. Roviello G, Gatta Michelet MR, D’AngeloA, Nobili S, Mini E. Role of novel hormonaltherapies in the management of non-metastaticcastration-resistant prostate cancer: a literaturebasedmeta-analysis of randomized trials.Clinical & Translational Oncology: OfficialPublication of the Federation of Spanish OncologySocieties and of the National Cancer Institute ofMexico. 2020;22(7): 1033–1039. https://doi.org/10.1007/s12094-019-02228-2.

  8. Hussain M, Fizazi K, Saad F, Rathenborg P,Shore N, Ferreira U, et al. Enzalutamide inMen with Nonmetastatic, Castration-ResistantProstate Cancer. New England Journal ofMedicine. 2018;378(26): 2465–2474. https://doi.org/10.1056/NEJMoa1800536.

  9. Burki T. Darolutamide for non-metastatic,castration-resistant prostate cancer. The LancetOncology. 2019;20(3): e139. https://doi.org/10.1016/S1470-2045(19)30102-0.

  10. Smith MR, Saad F, Chowdhury S, Oudard S,Hadaschik BA, Graff JN, et al. ApalutamideTreatment and Metastasis-free Survival inProstate Cancer. New England Journal ofMedicine. 2018;378(15): 1408–1418. https://doi.org/10.1056/NEJMoa1715546.

  11. Hegemann M, Bedke J, Stenzl A, TodenhöferT. Denosumab treatment in the management ofpatients with advanced prostate cancer: clinicalevidence and experience. Therapeutic Advancesin Urology. 2017;9(3–4): 81–88. https://doi.org/10.1177/1756287216686018.

  12. Boudadi K, Antonarakis ES. Resistance toNovel Antiandrogen Therapies in MetastaticCastration-Resistant Prostate Cancer. ClinicalMedicine Insights. Oncology. 2016;10(Suppl 1):1–9. https://doi.org/10.4137/CMO.S34534.

  13. Clegg NJ, Wongvipat J, Joseph JD, Tran C,Ouk S, Dilhas A, et al. ARN-509: a novelantiandrogen for prostate cancer treatment.Cancer Research. 2012;72(6): 1494–1503.https://doi.org/10.1158/0008-5472.CAN-11-3948.

  14. Heinrich D, Russnes KM, Oldenburg J. Re:Apalutamide Treatment and MetastasisfreeSurvival in Prostate Cancer. EuropeanUrology. 2018;74(2): 236–237. https://doi.org/10.1016/j.eururo.2018.04.010.

  15. Taneja SS. Re: Enzalutamide in Menwith Nonmetastatic, Castration-ResistantProstate Cancer. The Journal of Urology.2019;201(1): 31. https://doi.org/10.1097/01.ju.0000550155.71767.b1.

  16. Penson DF, Armstrong AJ, ConcepcionR, Agarwal N, Olsson C, Karsh L, et al.Enzalutamide Versus Bicalutamide inCastration-Resistant Prostate Cancer: TheSTRIVE Trial. Journal of Clinical Oncology:Official Journal of the American Society ofClinical Oncology. 2016;34(18): 2098–2106.https://doi.org/10.1200/JCO.2015.64.9285.




2020     |     www.medigraphic.com